The autophagy-lysosomal pathway (ALP) represents one of the fundamental cellular degradation systems essential for neuronal health and survival. This pathway encompasses the coordinated processes of autophagy and lysosomal degradation, which together constitute the cell's primary mechanism for removing damaged proteins, dysfunctional organelles, and pathogenic aggregates [1][2]. In neurons—post-mitotic cells that cannot divide and therefore cannot dilute accumulated damage through cell division—the proper functioning of the autophagy-lysosomal system is particularly critical for maintaining cellular homeostasis and preventing neurodegeneration [3].
Autophagy-lysosomal dysfunction has emerged as a central pathological mechanism in virtually all major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) [4][5]. The failure of this degradation pathway leads to the progressive accumulation of toxic protein aggregates, damaged mitochondria, and other cellular debris, ultimately resulting in neuronal death and the characteristic clinical manifestations of these disorders [6].
Neurons are highly specialized cells with unique metabolic demands and structural complexity. Unlike most other cell types, neurons are post-mitotic—they cannot undergo cell division and must therefore maintain proteostatic balance throughout the lifespan [7]. This makes them exceptionally dependent on efficient protein quality control mechanisms, including the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) [8].
The autophagy-lysosomal pathway comprises multiple interconnected processes: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), each with distinct mechanisms and cellular functions [9]. These processes converge at the lysosome, where cargo is degraded and recycled into basic building blocks for cellular reuse [10]. Any disruption at any point in this cascade—from autophagosome formation to lysosomal fusion and degradation—can have catastrophic consequences for neuronal health [11].
Macroautophagy is the best-characterized form of autophagy and involves the formation of double-membraned vesicles called autophagosomes that engulf cytoplasmic cargo [12]. This process is regulated by a conserved family of autophagy-related (ATG) proteins, which coordinate the initiation, nucleation, expansion, and closure of the phagophore membrane [13].
The initiation of macroautophagy is controlled by two key protein complexes: the ULK1 complex (containing ULK1/2, ATG13, FIP200, and ATG101) and the class III PI3K complex (containing Beclin-1, Vps34, Vps15, and ATG14L) [14]. Under nutrient-rich conditions, mTORC1 phosphorylates and inhibits the ULK1 complex, suppressing autophagy. During starvation or cellular stress, mTORC1 is inactivated, allowing ULK1 to initiate autophagosome formation [15].
The nucleation step involves the recruitment of the class III PI3K complex to the phagophore assembly site (PAS), where it produces phosphatidylinositol 3-phosphate (PI3P) that recruits additional ATG proteins for membrane expansion [16]. The elongation and closure of the autophagosome requires two ubiquitin-like conjugation systems: the ATG12-ATG5-ATG16L1 system and the LC3-II (microtubule-associated protein 1A/1B-light chain 3) system [17]. LC3-II, the lipidated form of LC3, is commonly used as a marker for autophagosomes in research studies [18].
Microautophagy involves the direct engulfment of cytoplasmic material by the lysosomal membrane through invagination, protrusion, or septation [19]. While less well-characterized than macroautophagy, microautophagy plays important roles in nutrient recycling and cellular homeostasis [20]. In mammals, microautophagy contributes to the degradation of long-lived proteins and damaged organelles, although the molecular mechanisms differ from those of macroautophagy [21].
Chaperone-mediated autophagy (CMA) represents a highly selective form of autophagy that does not involve vesicle formation [22]. Instead, cytosolic proteins containing a specific pentapeptide motif (KFERQ) are recognized by the heat shock cognate 70 kDa protein (HSC70) and its co-chaperones [23]. These chaperone-cargo complexes bind to LAMP-2A (lysosome-associated membrane protein type 2A) receptors on the lysosomal membrane, leading to substrate unfolding and translocation into the lysosomal lumen for degradation [24].
CMA plays crucial roles in quality control, metabolic regulation, and cellular stress responses [25]. Importantly, CMA selectively degrades specific proteins, including those involved in neurodegeneration such as α-synuclein, tau, and mutant huntingtin [26][27]. The regulation of CMA is complex, involving transcriptional control of LAMP-2A, lysosomal membrane dynamics, and co-chaperone activity [28].
Lysosomes are membrane-bound organelles containing hydrolytic enzymes capable of degrading all major classes of biological molecules [29]. The lysosomal lumen maintains an acidic pH (4.5-5.0) optimal for the activity of these hydrolases, which include proteases, nucleases, lipases, and glycosidases [30]. Beyond their degradative function, lysosomes serve as signaling hubs that coordinate cellular metabolism, nutrient sensing, and stress responses [31].
Lysosome biogenesis involves the coordinated expression of lysosomal hydrolases and membrane proteins, which are synthesized in the endoplasmic reticulum and transported through the Golgi apparatus to late endosomes/lysosomes [32]. The transcription factor TFEB (transcription factor EB) and its paralogs TFE3 and MITF master-regulate lysosomal biogenesis by binding to the CLEAR (coordinated lysosomal expression and regulation) element in the promoters of lysosomal and autophagy genes [33].
Lysosomal dysfunction is increasingly recognized as a critical contributor to neurodegenerative disease pathogenesis [34]. Multiple mechanisms can impair lysosomal function:
Lysosomal enzyme deficiency: Mutations in genes encoding lysosomal hydrolases cause lysosomal storage disorders, many of which present with neurological symptoms [35].
Impaired lysosomal acidification: Proper acidification is essential for hydrolase activity. V-ATPase dysfunction can impair lysosomal degradation [36].
Lysosomal membrane permeability: Damage to the lysosomal membrane releases hydrolyases into the cytoplasm, causing cellular stress and potentially triggering apoptosis [37].
Impaired autophagosome-lysosome fusion: Defects in the machinery required for fusion (e.g., SNARE proteins, VAMP8, syntaxin-17) impair cargo degradation [38].
Accumulation of undegraded material: Lipofuscin and other aggregates accumulate with aging and in disease states [39].
Alzheimer's disease (AD) is characterized by the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein [40]. Autophagy-lysosomal dysfunction contributes to the pathogenesis of AD at multiple levels [41].
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, metabolism, and autophagy [42]. In AD, mTOR signaling is hyperactive, contributing to multiple pathological features [43]. mTOR hyperactivity:
Post-mortem brain tissue from AD patients shows marked accumulation of autophagic vesicles (AVs) in dystrophic neurites surrounding amyloid plaques [48]. These AVs contain incompletely degraded Aβ and APP derivatives, indicating impaired autophagic-lysosomal degradation [49]. The accumulation of AVs reflects both increased autophagosome formation and impaired clearance [50].
Lysosomal dysfunction is evident in AD through:
Beclin-1, a key initiator of autophagy, is reduced in AD brains [55]. Genetic deletion of BECN1 in mice causes neurodegeneration and enhances Aβ accumulation, while beclin-1 overexpression improves autophagy and reduces amyloid pathology [56][57].
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies, cytoplasmic inclusions primarily composed of α-synuclein [58]. Autophagy-lysosomal dysfunction plays a central role in PD pathogenesis [59].
α-Synuclein is degraded by both the ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway [60]. Under physiological conditions, CMA efficiently degrades monomeric α-synuclein [61]. However, several factors impair α-synuclein clearance in PD:
Glucocerebrosidase (GBA) mutations are the most significant genetic risk factor for PD (except forLRRK2 and SNCA mutations) [65]. GBA encodes the lysosomal enzyme glucocerebrosidase, which catalyzes the hydrolysis of glucosylceramide to ceramide and glucose [66]. GBA deficiency leads to:
LAMP-2A deficiency causes Danon disease, an X-linked lysosomal storage disorder characterized by cardiomyopathy, myopathy, and dementia [71]. Importantly, LAMP-2A is the receptor for CMA, and its deficiency leads to widespread CMA dysfunction [72]. Studies have shown reduced LAMP-2A expression in PD brains, linking CMA impairment to sporadic PD [73].
The PINK1/Parkin pathway regulates mitophagy—the selective autophagy of damaged mitochondria [74]. Mutations in PINK1 (PARK6) and PRKN (PARK2) cause autosomal recessive juvenile Parkinsonism [75]. Impaired mitophagy leads to accumulation of dysfunctional mitochondria, increased oxidative stress, and neuronal death [76].
Huntington's disease (HD) is caused by CAG trinucleotide repeat expansion in the HTT gene, encoding mutant huntingtin (mHtt) protein [77]. mHtt impairs multiple steps of autophagy:
ALS is characterized by progressive motor neuron degeneration [82]. Autophagy-lysosomal dysfunction contributes to ALS pathogenesis through:
FTD encompasses a group of disorders characterized by frontal and temporal lobe atrophy [87]. Autophagy-lysosomal dysfunction is implicated in FTD through:
| Protein/Gene | Function | Disease Association |
|---|---|---|
| mTOR | Master regulator of autophagy initiation | Hyperactive in AD |
| ULK1/2 | Initiation complex kinase | Dysregulated in disease |
| Beclin-1 | PI3K complex component | Reduced in AD |
| ATG5, ATG7 | Autophagosome formation | Genetic variants in PD |
| LC3 (MAP1LC3) | Autophagosome marker | Altered in neurodegeneration |
| p62/SQSTM1 | Selective autophagy receptor | Aggregates in disease |
| LAMP-2A | CMA receptor | Reduced in PD |
| GBA | Lysosomal enzyme | PD risk factor |
| Cathepsin D | Lysosomal protease | Reduced in AD |
| TFEB | Lysosomal biogenesis regulator | Therapeutic target |
| PINK1 | Mitophagy initiation | PARK6 mutations cause PD |
| Parkin | E3 ubiquitin ligase | PARK2 mutations cause PD |
Clinical trials of mTOR inhibitors in AD and PD have shown mixed results, likely due to the complex role of mTOR in neuronal function [94][95].
Multiple clinical trials are investigating autophagy-lysosomal modulators in neurodegenerative diseases:
Biomarkers for autophagy-lysosomal dysfunction are being developed:
Autophagy-lysosomal dysfunction represents a central pathological mechanism across neurodegenerative diseases. The unique vulnerability of neurons to impaired protein quality control, combined with the complexity of autophagy-lysosomal regulation, creates multiple therapeutic targets. While pharmacological modulation of autophagy shows promise, the challenge lies in achieving sufficient pathway activation without disrupting normal cellular function. Future approaches will likely combine biomarker-driven patient selection with targeted modulation of specific autophagy-lysosomal components.
Nixon RA. The role of autophagy in neurodegenerative disease. 2013. ↩︎
Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. 2011. ↩︎
Kourtis N, Tavernarakis N. Autophagy and cell death in Caenorhabditis elegans. 2009. ↩︎
Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. 2015. ↩︎
Yamamoto A, Yue Z. Autophagy and its normal and pathogenic roles in the brain. 2014. ↩︎
Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. 2010. ↩︎
Hipkiss AR. Aging, proteotoxicity, neurodegeneration, Glyoxal, and methylglyoxal: facts and perspectives. 2007. ↩︎
Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. 2015. ↩︎
Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. 2021. ↩︎
Lawrence RE, Zun G. The mechanism of macroautophagy. 2017. ↩︎
Bento CF, et al. Mammalian autophagy: core molecular machinery and signaling regulation. 2020. ↩︎
Reggiori F, Klionsky DJ. Autophagosomes: biogenesis from scratch. 2005. ↩︎
Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. 2001. ↩︎
Russell RC, et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. 2013. ↩︎
Egan DF, et al. Phosphorylation of ULK1 by AMPK initiates autophagy. 2011. ↩︎
Burman C, Ktistakis NT. Regulation of autophagy by phosphatidylinositol 3-phosphate. 2010. ↩︎
Mizushima N, et al. A ubiquitin-like system mediates protein lipidation. 2000. ↩︎
Kabeya Y, et al. LC3, a mammalian homolog of yeast Apg8p, is localized in autophagosome membranes after processing. 2000. ↩︎
Mijaljica D, Prescott M, Devenish RJ. Microautophagy in mammalian cells: revisiting a 40-year-old conundrum. 2011. ↩︎
Li WW, Li J, Bao JK. Microautophagy: lesser-known self-eating. 2012. ↩︎
Sahu R, et al. Microautophagy of cytosolic proteins by late endosomes. 2011. ↩︎
Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. 2014. ↩︎
Dice JF. [Peptide sequences that target cytosolic proteins for lysosomal proteolysis](https://doi.org/10.1016/0968-0004(90). 1990. ↩︎
Cuervo AM, Mann L, Bonten EJ, d'Azzo A, Dice JF. Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor. 2003. ↩︎
Kiffin R, et al. Dynamic changes in the selectivity of chaperone-mediated autophagy. 2004. ↩︎
Cuervo AM, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. 2004. ↩︎
Martinez-Vicente M, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. 2010. ↩︎
Koga H, et al. Lamp-2a regulates lifespan in Drosophila. 2011. ↩︎
De Duve C. The lysosome turns fifty. 2005. ↩︎
Mindell JA. Lysosomal acidification mechanisms. 2012. ↩︎
Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. 2013. ↩︎
Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. 2009. ↩︎
Sardiello M, et al. A gene network regulating lysosomal biogenesis and function. 2009. ↩︎
Boland B, et al. Autophagy induction and autophagic cell death in AD neurons. 2008. ↩︎
Walkley SU. Pathogenic mechanisms in lysosomal disease. 2003. ↩︎
Colacurcio DJ, Nixon RA. Disorders of lysosomal acidification—the emerging role of v-ATPase in aging and neurodegeneration. 2016. ↩︎
Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. 2008. ↩︎
Itakura E, Kishi-Itakura C, Mizushima N. The hairpin-type tail-anchored SNARE syntaxin 17 specifies autophagosome fusion with lysosomes. 2012. ↩︎
Terman A, Brunk UT. Lipofuscin. 2004. ↩︎
Hardy J, Selkoe DJ. The amyloid hypothesis of AD: progress and problems on the road to therapeutics. 2002. ↩︎
Nixon RA, Yang DS. Autophagy failure in AD—a possible therapeutic target. 2012. ↩︎
Laplante M, Sabatini DM. mTOR signaling in growth, metabolism, and disease. 2012. ↩︎
Caccamo A, et al. Molecular interplay between mTOR, Aβ, and tau: effects on cognitive impairments. 2010. ↩︎
Kim J, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. 2011. ↩︎
Boland B, et al. Autophagy induction and autophagic cell death in AD neurons. 2008. ↩︎
Oddo S. The role of mTOR signaling in AD. 2013. ↩︎
Meshram SN, et al. mTOR and tau pathology. 2019. ↩︎
Nixon RA, et al. Extensive lysosomal involvement in AD. 2005. ↩︎
Yu WH, et al. Autophagic-lysosomal participation in AD. 2005. ↩︎
Lee JH, et al. Lysosomal proteolysis and autophagy in AD. 2010. ↩︎
Cataldo AM, et al. [Endocytic pathway abnormalities in AD](https://doi.org/10.1016/0896-6273(95). 1995. ↩︎
Lee JH, et al. Lysosomal acidification defects in AD. 2010. ↩︎
Bordi M, et al. Autophagy dysregulation in AD. 2016. ↩︎
Poduri A, et al. Genetic variation in autophagy genes in AD. 2013. ↩︎
Rohn TT, et al. Beclin-1 expression in AD brain. 2011. ↩︎
Pickford F, et al. Beclin-1 regulates autophagy in AD. 2008. ↩︎
Jaeger PA, et al. Effects of beclin-1 overexpression in AD. 2010. ↩︎
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. 1997. ↩︎
Lynch-Day MA, et al. The role of autophagy in PD. 2012. ↩︎
Ebrahimi-Fakhari D, et al. Degradation of α-synuclein by macroautophagy. 2011. ↩︎
Cuervo AM, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. 2004. ↩︎
Cuervo AM, et al. CMA and α-synuclein in PD. 2005. ↩︎
Martinez-Vicente M, et al. Alpha-synuclein and oxidative stress. 2010. ↩︎
Vogiatzi T, et al. Alpha-synuclein oligomers and autophagy. 2008. ↩︎
Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in PD. 2009. ↩︎
Beavan MS, Schapira AH. Glucocerebrosidase mutations and PD. 2013. ↩︎
Gegg ME, et al. Glucocerebrosidase deficiency in PD. 2012. ↩︎
Mazzulli JR, et al. Gaucher disease glucocerebrosidase and α-synuclein. 2011. ↩︎
Cleeter MW, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction. 2013. ↩︎
Schapira AH, Gegg ME. Glucocerebrosidase in PD. 2012. ↩︎
Danon MJ, et al. Lysosomal myopathy. 1986. ↩︎
Koga H, Cuervo AM. LAMP-2 deficiency in PD. 2011. ↩︎
Xilouri M, et al. LAMP-2a in PD. 2013. ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial quality control. 2015. ↩︎
Valente EM, et al. PINK1 mutations in PD. 2004. ↩︎
Jin SM, Youle RJ. PINK1- and Parkin-mediated mitophagy. 2012. ↩︎
[The Huntington's Disease Collaborative Research Project. A novel gene containing a trinucleotide repeat. Cell. 1993;72(6):971-983](https://doi.org/10.1016/0092-8674(93). 1993. ↩︎
Atwal RS, et al. Huntingtin has a membrane association signal that can modulate huntingtin aggregation. 2007. ↩︎
Ravikumar B, et al. Inhibition of mTOR induces autophagy. 2002. ↩︎
Wong E, et al. Autophagy inhibition in Huntington's disease. 2008. ↩︎
Martinez-Vicente M, et al. Cargo recognition failure in HD. 2010. ↩︎
Ferraiuolo L, et al. Molecular pathways of ALS. 2011. ↩︎
Liu FT, et al. Genetic variants in autophagy genes in ALS. 2015. ↩︎
Chen S, et al. Autophagy in ALS. 2012. ↩︎
Liu J, et al. Lysosomal membrane permeabilization in ALS. 2015. ↩︎
Lee JK, et al. Protein aggregates in ALS. 2014. ↩︎
Rascovsky K, et al. Diagnostic criteria for FTD. 2011. ↩︎
Baker M, et al. Mutations in progranulin cause FTD. 2006. ↩︎
Khurana V, Lindquist G. Tauopathy in FTD. 2011. ↩︎
Watts GD, et al. VCP mutations in FTD and ALS. 2004. ↩︎
Spilman P, et al. Rapamycin improves learning in AD. 2010. ↩︎
Bove J, et al. Neuroprotection by rapamycin in PD. 2011. ↩︎
Thoreen CC, et al. An ATP-competitive mTOR inhibitor. 2009. ↩︎
Zhang J, et al. mTOR inhibitors in AD clinical trials. 2017. ↩︎
Malagelada C, et al. Rapamycin in PD. 2011. ↩︎
Song JX, et al. Carbamazepine as autophagy enhancer. 2013. ↩︎
Sarkar S, et al. Trehalose enhances autophagy. 2007. ↩︎
Forlenza OV, et al. Lithium effects in neurodegenerative diseases. 2015. ↩︎
Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium. 2010. ↩︎
Bremova T, et al. Acetyl-DL-leucine in lysosomal disorders. 2015. ↩︎
Vecsey L, et al. 2-hydroxypropyl-β-cyclodextrin. 2014. ↩︎
Alfaro ME, et al. GBA modulators for PD. 2018. ↩︎
Zhang J, et al. AAV-mediated gene therapy for neurodegenerative diseases. 2013. ↩︎
Koga H, et al. LAMP-2a gene therapy. 2011. ↩︎
Sardi SP, et al. GBA gene therapy for PD. 2017. ↩︎
Decressac M, et al. TFEB gene therapy. 2013. ↩︎
Rubinsztein DC, et al. Autophagy and aging. 2011. ↩︎
Mattson MP. Energy intake and exercise as determinants of brain health. 2020. ↩︎
He C, et al. Exercise induces autophagy. 2017. ↩︎
Newman JC, Verdin E. Ketone bodies as signaling metabolites. 2014. ↩︎
D'Amico M, et al. CSF biomarkers of autophagy in AD. 2019. ↩︎
Wu MY, et al. Autophagy flux in peripheral blood mononuclear cells. 2016. ↩︎
Bladowska J, et al. Lysosomal imaging in neurodegeneration. 2020. ↩︎
Gatica D, et al. Selective autophagy. 2022. ↩︎
Song JX, et al. Targeting UPS-autophagy crosstalk. 2020. ↩︎
Ioannou MS, et al. Neuron-astrocyte metabolic coupling. 2019. ↩︎
Fetahu IS, et al. Epigenetic regulation of autophagy. 2019. ↩︎
Sances S, et al. iPSC-derived neurons for drug screening. 2016. ↩︎